Standard Dose of Allopurinol
Start allopurinol at 100 mg daily and titrate upward by 100 mg increments every 2-4 weeks until serum uric acid is <6 mg/dL (360 μmol/L), with a maximum dose of 800 mg daily. This "start low, go slow" approach is the cornerstone of safe and effective urate-lowering therapy.
Initial Dosing Strategy
The 2016 EULAR guidelines 1 and 2020 ACR guidelines 2 both strongly recommend starting allopurinol at 100 mg daily (or lower in patients with chronic kidney disease stage ≥3). The FDA label 3 confirms this approach, stating that starting with a low dose reduces the possibility of acute gouty flare-ups.
Key principle: Never start at 300 mg daily, despite this being common practice in many regions. Starting doses above 100 mg significantly increase the risk of allopurinol hypersensitivity syndrome (AHS), particularly when not adjusted for renal function 4.
Dose Titration Protocol
- Increase by 100 mg increments every 2-4 weeks until target serum uric acid is achieved 1, 2
- Target serum uric acid: <6 mg/dL (360 μmol/L) for all patients
- Lower target (<5 mg/dL): Consider for severe gout with tophi, chronic arthropathy, or frequent attacks until crystal dissolution occurs 1
- Maximum dose: 800 mg daily per FDA label 3
Most patients achieve target serum uric acid within 2-3 months at relatively modest doses. Research shows the median effective dose is 200 mg daily, with 80% of patients reaching target by 3 months 5. A randomized controlled trial demonstrated that 69% of patients achieved target with dose escalation versus only 32% remaining on fixed doses 6.
Maintenance Dosing by Disease Severity
The FDA label 3 provides specific guidance:
- Mild gout: Average 200-300 mg/day
- Moderately severe tophaceous gout: Average 400-600 mg/day
- Minimal effective dose: 100-200 mg daily
- Doses >300 mg: Should be administered in divided doses
Renal Dose Adjustment
Critical caveat: Dose adjustment for renal impairment is essential to prevent AHS, but should not prevent achieving therapeutic targets.
Per EULAR guidelines 1 and FDA label 3:
- CrCl 10-20 mL/min: Maximum 200 mg daily
- CrCl <10 mL/min: Maximum 100 mg daily
- CrCl <3 mL/min: May need to lengthen dosing intervals
Important nuance: The 2020 ACR guidelines 2 note that while higher starting doses and CKD increase AHS risk, patients with CKD may still require dose titration above 300 mg/day to achieve target serum uric acid. Start at ≤50 mg daily in severe CKD, then titrate carefully 2.
Prophylaxis During Initiation
Mandatory: Provide anti-inflammatory prophylaxis for the first 3-6 months when starting or escalating allopurinol 1, 2.
Options include:
- Colchicine 0.5-1 mg daily (reduce dose in renal impairment)
- Low-dose NSAIDs (if not contraindicated)
- Prednisone/prednisolone (if colchicine and NSAIDs contraindicated)
Continue prophylaxis for at least 6 months or longer if flares persist 1, 2.
Common Pitfalls to Avoid
Fixed 300 mg dosing: This fails to achieve target serum uric acid in approximately 70% of patients and perpetuates inadequate gout control 6, 7
Excessive dose reduction in renal impairment: While starting doses must be lower, many patients with CKD can safely tolerate higher maintenance doses when titrated gradually 2, 6
Starting dose too high: Starting above 100 mg (or >1.5 mg per unit of estimated GFR) significantly increases AHS risk 4
Not monitoring serum uric acid: Titrate to biochemical target, not arbitrary dose limits 1
Stopping at first flare: Flares during initiation are common and expected; continue allopurinol with adequate prophylaxis rather than discontinuing 1, 2
When to Switch Therapy
If target serum uric acid cannot be achieved at appropriate allopurinol doses (accounting for renal function), switch to or add:
- Febuxostat (alternative xanthine oxidase inhibitor)
- Uricosuric agents (probenecid, benzbromarone)
- Combination therapy (allopurinol + uricosuric)
Per EULAR guidelines 1, this decision should be made when maximum appropriate allopurinol dosing fails to achieve target, not prematurely.